Literature DB >> 8857719

Is the comorbidity of epilepsy and migraine due to a shared genetic susceptibility?

R Ottman1, R B Lipton.   

Abstract

We tested the hypothesis that the comorbidity of migraine and epilepsy results from a shared genetic susceptibility to the two disorders. We used semistructured telephone interviews to collect information on migraine and epilepsy in the families (parents, siblings, and offspring) of 1,967 adult probands with epilepsy. Epilepsy was defined as a lifetime history of two or more unprovoked seizures, and migraine as self-reported severe headaches with two or more of the following symptoms: unilateral pain, throbbing pain, visual aura, or nausea. As a first test of the hypothesis of shared susceptibility, we assessed risk of migraine in relatives of probands with genetic versus nongenetic forms of epilepsy, using two proxy measures of genetic susceptibility-a first-degree family history of epilepsy and idiopathic/cryptogenic (versus postnatal symptomatic) etiology. Neither of these two measures was associated with risk of migraine in relatives. As a second test, we assessed risk of epilepsy in the relatives of probands with versus without migraine. With the exception of one subgroup (sons of female probands), risk of epilepsy in relatives was not associated with the proband's history of migraine. This pattern of results is inconsistent with the hypothesis of a shared genetic susceptibility to migraine and epilepsy.

Entities:  

Mesh:

Year:  1996        PMID: 8857719      PMCID: PMC2791701          DOI: 10.1212/wnl.47.4.918

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis.

Authors:  R B Lipton; W F Stewart; D D Celentano; M L Reed
Journal:  Arch Intern Med       Date:  1992-06

2.  Simple test of the Multifactorial-Polygenic Model with sex dependent thresholds.

Authors:  R Ottman
Journal:  J Chronic Dis       Date:  1987

3.  Bias in analytic research.

Authors:  D L Sackett
Journal:  J Chronic Dis       Date:  1979

4.  Semistructured interview for seizure classification: agreement with physicians' diagnoses.

Authors:  R Ottman; W A Hauser; L Stallone
Journal:  Epilepsia       Date:  1990 Jan-Feb       Impact factor: 5.864

5.  Data collection strategies in genetic epidemiology: The Epilepsy Family Study of Columbia University.

Authors:  R Ottman; M Susser
Journal:  J Clin Epidemiol       Date:  1992-07       Impact factor: 6.437

6.  A gene for familial hemiplegic migraine maps to chromosome 19.

Authors:  A Joutel; M G Bousser; V Biousse; P Labauge; H Chabriat; A Nibbio; J Maciazek; B Meyer; M A Bach; J Weissenbach
Journal:  Nat Genet       Date:  1993-09       Impact factor: 38.330

7.  Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy.

Authors: 
Journal:  Epilepsia       Date:  1981-08       Impact factor: 5.864

8.  Reliability of seizure classification using a semistructured interview.

Authors:  R Ottman; J H Lee; W A Hauser; S Hong; D Hesdorffer; N Schupf; T A Pedley; M L Scheuer
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

9.  Prevalence of epilepsy in Rochester, Minnesota: 1940-1980.

Authors:  W A Hauser; J F Annegers; L T Kurland
Journal:  Epilepsia       Date:  1991 Jul-Aug       Impact factor: 5.864

10.  Validity of family history data on severe headache and migraine.

Authors:  R Ottman; S Hong; R B Lipton
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

View more
  13 in total

1.  Migraine attack triggering a generalised seizure: is this a case of migralepsy or ictal epileptic headache?

Authors:  Angelo Labate; Miriam Sturniolo; Franco Pucci; Aldo Quattrone; Antonio Gambardella
Journal:  Neurol Sci       Date:  2011-11-08       Impact factor: 3.307

2.  Evidence for a shared genetic susceptibility to migraine and epilepsy.

Authors:  Melodie R Winawer; Robert Connors
Journal:  Epilepsia       Date:  2013-01-07       Impact factor: 5.864

3.  Hemiplegic migraine and late-onset photosensitive epileptic seizures.

Authors:  Domenico Chirchiglia; Attilio Della Torre; Giorgio Volpentesta; Serena Marianna Lavano; Angelo Lavano; Giuseppe Borzi'
Journal:  Neurol Sci       Date:  2016-07-12       Impact factor: 3.307

4.  Migraine comorbidity and cognitive performance in patients with focal epilepsy.

Authors:  Olivia A J Begasse de Dhaem; Jacqueline French; Chris Morrison; Kimford J Meador; Dale C Hesdorffer; Sabrina Cristofaro; Mia T Minen
Journal:  Epilepsy Behav       Date:  2019-06-07       Impact factor: 2.937

5.  Comorbidity between headache and epilepsy in a pediatric headache center.

Authors:  Irene Toldo; Egle Perissinotto; Francesca Menegazzo; Clementina Boniver; Stefano Sartori; Leonardo Salviati; Maurizio Clementi; Pasquale Montagna; Pier Antonio Battistella
Journal:  J Headache Pain       Date:  2010-01-29       Impact factor: 7.277

Review 6.  Migralepsy: a borderland of wavy lines.

Authors:  Amy Z Crepeau
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

Review 7.  Epidemiology of migraine.

Authors:  S W Hamelsky; W F Stewart; R B Lipton
Journal:  Curr Pain Headache Rep       Date:  2001-04

Review 8.  Chronic disorders with episodic manifestations: focus on epilepsy and migraine.

Authors:  Sheryl R Haut; Marcelo E Bigal; Richard B Lipton
Journal:  Lancet Neurol       Date:  2006-02       Impact factor: 44.182

Review 9.  Migraine-associated risks and comorbidity.

Authors:  H C Diener; M Küper; T Kurth
Journal:  J Neurol       Date:  2008-09-30       Impact factor: 4.849

10.  Ezogabine (KCNQ2/3 channel opener) prevents delayed activation of meningeal nociceptors if given before but not after the occurrence of cortical spreading depression.

Authors:  XiChun Zhang; Moshe Jakubowski; Catherine Buettner; Vanessa Kainz; Michael Gold; Rami Burstein
Journal:  Epilepsy Behav       Date:  2013-04-05       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.